OAM
DMK

Oxford Asset Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Oxford Asset Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,612
Closed -$254K – 2075
2018
Q4 		$254K Buy
+1,612
New +$309K 0.01% 1462

Other funds holding DMK

First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Oxford Asset Management's DMK Position: Q1 2019 in Review

Oxford Asset Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2019, closing a stake of 1,612 shares — an estimated $254K sold.

Oxford Asset Management first reported a position in DMK in Q4 2018 and held it in 1 quarter. The position peaked at $254K in Q4 2018. 57 funds tracked by Wall St. Rank hold DMK as of Q1 2019.

  • Oxford Asset Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 1,612 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2019, an estimated $254K.
  • Oxford Asset Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $254K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.